NHP National Voxelotor Guideline

Written By U'mau Otuokon

In January 2022 Voxelotor was given a positive Scientific opinion for the Early Access to Medicine Scheme (EAMS), which programme allows for promising new unlicensed medicines to be used outside their licence, to UK patients that have a high unmet clinical need.

The guideline for use has been published by the National Haemoglobinopathy Panel working group.

Access the document here.

U'mau Otuokon
Previous

NHP Acute Pain Action Plan published

Next

NHP Annual Report 2020/2021